CD38KO NK cell therapy has the potential to maximize the efficacy of anti-CD38 against multiple myeloma Amsterdam, The Netherlands, July 22, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative cell therapeutics for life-threatening diseases, today announces publication of an article in Blood, Journal of the… Continue reading Kiadis announces publication in Blood highlighting proof-of-concept to enhance potency of anti-CD38 antibodies with Kiadis’ K-NK004, recently licensed by Sanofi
Blog posts
Kiadis appoints Ray Barlow, Ph.D. as Chief Business Officer and Govert Schouten, Ph.D. as Head of Innovation to Kiadis Management Team
Senior executives with extensive biotechnology and pharmaceutical industry, science, innovation and business development experience Bringing unique capabilities to unlock broad potential of Kiadis platform Amsterdam, The Netherlands, July 13, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative NK-cell therapeutics for patients with… Continue reading Kiadis appoints Ray Barlow, Ph.D. as Chief Business Officer and Govert Schouten, Ph.D. as Head of Innovation to Kiadis Management Team
Kiadis licenses previously undisclosed pre-clinical K-NK-cell programs to Sanofi, with total potential deal value of €875 million, plus royalties
Combination of Kiadis’ CD38 knock out K-NK cells with Sanofi’s anti-CD38 antibody Sarclisa® enables optimal tumor cell killing, and offers a potential first-in-class treatment for patients with multiple myeloma Kiadis receives €17.5 million up front payment; potential for up to €857.5 million in preclinical, clinical, regulatory and commercial milestone payments, and up to double-digit royalties … Continue reading Kiadis licenses previously undisclosed pre-clinical K-NK-cell programs to Sanofi, with total potential deal value of €875 million, plus royalties
Kiadis Pharma files first investigational new drug application with the U.S. FDA for natural killer (NK) cell therapy produced with PM21
IND supports the Company’s planned NK-REALM Phase 1/2 study which will evaluate K-NK002 in 63 patients with blood cancer undergoing a haploidentical hematopoietic stem cell transplant (HSCT) Amsterdam, The Netherlands, April 9, 2020 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announced that… Continue reading Kiadis Pharma files first investigational new drug application with the U.S. FDA for natural killer (NK) cell therapy produced with PM21
Kiadis Pharma changes strategy to focus solely on development of Natural Killer (NK) Cell therapeutics and terminates development of ATIR101
Kiadis will focus all future investments on developing off-the-shelf and haplo donor NK-cell therapies for the treatment of solid and liquid tumors Discontinues development of ATIR101, stopping phase 3 trial Restructures organization; reducing workforce by approximately half Amsterdam, The Netherlands, 12 November 2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage… Continue reading Kiadis Pharma changes strategy to focus solely on development of Natural Killer (NK) Cell therapeutics and terminates development of ATIR101
